Sector Alpha

Track where the smart money flows in Indian equities

DashboardWeekly UpdateUploadPipelinePE CyclesBrainAbout

Data updated weekly. Not financial advice.

Sector Alpha
  1. Home
  2. /Momentum
  3. /Pharma - Formulators
  4. /Accent Microcell Ltd
MomentumDeep Value

Accent Microcell Ltd: Why Is It Outperforming Nifty 500?

Active
RS +43.8%Average12w StreakAccelerating

In Week of May 10, 2026, Accent Microcell Ltd (Pharma - Formulators) is outperforming Nifty 500 with +43.8% relative strength. Fundamentals: Average. On a 12-week streak.

Accent Microcell Ltd Key Facts

PE Ratio
32.5x
Price/Book
3.37x
Market Cap
₹1,127 Cr
PAT Growth YoY
+13%
Revenue Growth YoY
+10%
OPM
17.0%
RS vs Nifty 500
+43.8%
PE: Near PeakRiding Wave

What's Happening

📊PE near cycle highs — limited room for further expansion
💪Debt reduced 50% YoY — balance sheet strengthening
🏛️DII accumulation — stake up 1.6%
💰Trading 82% below estimated fair value — significant discount

Key Risks

1. Commodity
MEDIUM
2. Fx
MEDIUM
3. Regulatory
LOW

Key Numbers

PAT Growth YoY
+13%
Stable
Revenue YoY
+10%
Stable
Operating Margin
17.0%
+200 bps YoY
PE Ratio
32.5
PEG Ratio
0.45
EV/EBITDA
15.4
Current Price
₹470
Dividend Yield
0.21%
Fundamental Score
59/100
Average
3Y PAT CAGR
+77%
Market Cap
1.1K Cr
Valuation
Significantly Undervalued

12-Week Performance

Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.

12 weeks agoThis week

What Are the Key Risks for Accent Microcell Ltd?

Earnings deceleration risks from management commentary

Commodity

MEDIUM

Trigger: Wood pulp prices are driven by global paper/pulp supply-demand dynamics, which are outside Accent Microcell's control — making this a persistent earnings volatility driver

Monitor: commodity

Fx

MEDIUM

Trigger: INR appreciation of even 3-5% could compress PAT by 1.5-2% given the revenue exposure, which is material for a company with 17% OPM

Monitor: fx

Regulatory

LOW

Trigger: Expanding into regulated markets increases the compliance surface area — a US FDA audit is the key gating event for US market revenue growth

Monitor: regulatory

What Is Accent Microcell Ltd's Management Saying?

Key quotes from recent conference calls

“Commodity price risk remains central, as the company is sensitive to the cost of wood pulp and alpha cellulose [Risk (commodity): MEDIUM]”
“Foreign exchange risk is also active given that 45% of revenue is derived from exports, making the bottom line vulnerable to Rupee appreciation [Risk (fx): MEDIUM]”
“Targeting further penetration in regulated markets — shift toward high-purity MCC grades expected to support margin improvement [Risk (regulatory): LOW]”

How Fast Is Accent Microcell Ltd Growing?

Revenue, profit and margin growth rates

MetricYoY3Y CAGRTrend
Revenue+10%+17%Stable
PAT (Net Profit)+13%+77%Stable
OPM17.0%+200 bpsStable

The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 30, 2026.

Other Top Pharma - Formulators Stocks Beating Nifty 500

Sun Pharmaceutical Industries Ltd
Strong
+10.4%
Torrent Pharmaceuticals Ltd
Average • 12w streak
+12.6%
Lupin Ltd
Strong • 12w streak
+10.8%
Dr Reddys Laboratories Ltd
Average • 11w streak
+5.6%
Mankind Pharma Ltd
Average
+19.4%
← Back to Pharma - FormulatorsDashboard

Frequently Asked Questions: Accent Microcell Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Accent Microcell Ltd's latest quarterly results?

Accent Microcell Ltd's latest quarterly results (Sep 2025) show

  • PAT Growth YoY: +12.5% (stable)
  • Revenue Growth YoY: +10.3%
  • Operating Margin: 17.0% (stable)

Is Accent Microcell Ltd's profit growing or declining?

Accent Microcell Ltd's profit is growing with an stable trend.

  • PAT Growth YoY: +12.5% (latest quarter)
  • PAT Growth QoQ: +5.9% (sequential)
  • 3-Year PAT CAGR: +76.5%
  • Trend: Stable — consistent growth pattern

What is Accent Microcell Ltd's revenue growth trend?

Accent Microcell Ltd's revenue growth trend is stable.

  • Revenue Growth YoY: +10.3%
  • Revenue Growth QoQ: 0.0% (sequential)
  • 3-Year Revenue CAGR: +16.9%

How is Accent Microcell Ltd's operating margin trending?

Accent Microcell Ltd's operating margin is stable.

  • Current OPM: 17.0%
  • OPM Change YoY: +2.0% basis points
  • OPM Change QoQ: 0.0% basis points

What is Accent Microcell Ltd's 3-year profit and revenue CAGR?

Accent Microcell Ltd's long-term compounding rates

  • 3-Year Profit CAGR: +76.5%
  • 3-Year Revenue CAGR: +16.9%

Is Accent Microcell Ltd's growth accelerating or decelerating?

Accent Microcell Ltd's earnings growth is stable with mixed signals on a sequential basis.

  • YoY Acceleration: +6.2% bps
  • Sequential Acceleration: -0.4% bps

Is Accent Microcell Ltd overvalued or undervalued?

Accent Microcell Ltd appears significantly undervalued based on our fair value analysis.

  • Valuation Signal: Significantly Undervalued
  • Current PE: 32.5x
  • Price-to-Book: 4.5x

What is Accent Microcell Ltd's current PE ratio?

Accent Microcell Ltd's current PE ratio is 32.5x.

  • Current PE: 32.5x
  • Market Cap: 1.1K Cr
  • Dividend Yield: 0.21%

How does Accent Microcell Ltd's valuation compare to its history?

Accent Microcell Ltd's current PE is 32.5x.

  • Current PE: 32.5x
  • Valuation Assessment: Significantly Undervalued

What is Accent Microcell Ltd's price-to-book ratio?

Accent Microcell Ltd's price-to-book ratio is 4.5x.

  • Price-to-Book (P/B): 4.5x
  • Book Value per Share: ₹104
  • Current Price: ₹470

Is Accent Microcell Ltd a fundamentally strong company?

Accent Microcell Ltd is rated Average with a fundamental score of 58.5/100. This score is calculated from objective financial metrics

  • Revenue Growth YoY: +10.3% (10% weight)
  • PAT Growth YoY: +12.5% (10% weight)
  • PAT Growth QoQ: +5.9% (10% weight)
  • Margins stable (10% weight)
  • PEG Ratio: 0.5x vs sector median (15% weight)
  • EV/EBITDA: 15.4x vs sector median (15% weight)

Is Accent Microcell Ltd debt free?

Accent Microcell Ltd has a debt-to-equity ratio of N/A.

  • Total Debt: ₹1 Cr

What is Accent Microcell Ltd's return on equity (ROE) and ROCE?

Accent Microcell Ltd's return ratios over recent years

  • FY2023: ROCE 27.0%
  • FY2024: ROCE 31.0%
  • FY2025: ROCE 24.0%

Is Accent Microcell Ltd's cash flow positive?

Accent Microcell Ltd's operating cash flow is positive (FY2025).

  • Cash from Operations (CFO): ₹25 Cr
  • Free Cash Flow (FCF): ₹16 Cr
  • CFO/PAT Ratio: 76% (adequate)

What is Accent Microcell Ltd's dividend yield?

Accent Microcell Ltd's current dividend yield is 0.21%.

  • Dividend Yield: 0.21%
  • Current Price: ₹470

Who holds Accent Microcell Ltd shares — promoters, FII, DII?

Accent Microcell Ltd's shareholding pattern (Mar 2026)

  • Promoters: 55.5%
  • FII (Foreign): 0.6%
  • DII (Domestic): 3.6%
  • Public: 40.4%

Is promoter holding increasing or decreasing in Accent Microcell Ltd?

Accent Microcell Ltd's promoter holding has increased recently.

  • Current Promoter Holding: 55.5% (Mar 2026)
  • Previous Quarter: 55.4% (Dec 2025)
  • Change: +0.03% (increasing — positive signal)

How long has Accent Microcell Ltd been outperforming Nifty 500?

Accent Microcell Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.

Is Accent Microcell Ltd a new momentum entry or an established outperformer?

Accent Microcell Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.

What are the key risks in Accent Microcell Ltd?

Accent Microcell Ltd has 3 key risks worth monitoring

  • [MEDIUM] Commodity — Wood pulp prices are driven by global paper/pulp supply-demand dynamics, which are outside Accent Microcell's control — making this a persistent earnings volatility driver
  • [MEDIUM] Fx — INR appreciation of even 3-5% could compress PAT by 1.5-2% given the revenue exposure, which is material for a company with 17% OPM
  • [LOW] Regulatory — Expanding into regulated markets increases the compliance surface area — a US FDA audit is the key gating event for US market revenue growth

What did Accent Microcell Ltd's management say in the latest earnings call?

In Q2 FY26, Accent Microcell Ltd's management highlighted

  • "Commodity price risk remains central, as the company is sensitive to the cost of wood pulp and alpha cellulose [Risk (commodity): MEDIUM]"
  • "Foreign exchange risk is also active given that 45% of revenue is derived from exports, making the bottom line vulnerable to Rupee appreciation [Risk..."
  • "Targeting further penetration in regulated markets — shift toward high-purity MCC grades expected to support margin improvement [Risk (regulatory): L..."

Is Accent Microcell Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Accent Microcell Ltd may be worth studying

  • Earnings growing at +12.5% YoY
  • Valuation: appears significantly undervalued
  • Cash flow is positive — CFO ₹25 Cr

What is the investment thesis for Accent Microcell Ltd?

Accent Microcell Ltd investment thesis summary:

Research Signals (Bull Case)

  • Revenue growing at +10.3% YoY
  • Appears significantly undervalued

Risk Factors (Bear Case)

  • Key risk: Commodity

What is the future outlook for Accent Microcell Ltd?

Accent Microcell Ltd's forward outlook based on current data signals

  • Earnings Trend: stable
  • Revenue Trend: stable
  • Margin Trend: stable
  • Valuation: Significantly Undervalued
  • Key Risk: Commodity

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.